Krystal Biotech, Inc. KRYS Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s operating lease liabilities (total)?
- Krystal Biotech, Inc. (KRYS) reported operating lease liabilities (total) of $9.11M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating lease liabilities (total) changed year-over-year?
- Krystal Biotech, Inc.'s operating lease liabilities (total) decreased by 5.7% year-over-year, from $9.66M to $9.11M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease liabilities (total) has grown at a 18.8% compound annual growth rate (CAGR), from $3.95M to $9.34M.
- What does operating lease liabilities (total) mean?
- The total value of future payments for leased assets like offices or equipment.
- How do you interpret operating lease liabilities (total)?
- An increase indicates expanded physical footprint or equipment leasing, while a decrease suggests lease expirations or downsizing.
- How does operating lease liabilities (total) compare across companies?
- Depends on the company's strategy regarding owning versus leasing facilities and equipment.